在合理样本量的随机对照试验中检测抗病毒药物对COVID-19的显著效果:一项建模研究
该建模研究基于SARS-CoV-2未治疗者的纵向病毒载量数据,用宿主内病毒动力学模型拟合,并按聚类分为3组,各组病毒衰减率显著不同(p<0.001)。模拟随机对照试验显示,若全部患者入组,检测抗病毒效果所需样本量巨大;若仅在症状出现1天内入组,样本量可大幅降低。
要点
- 个体间病毒动力学异质性大,观察性研究中的效应估计可能因此产生偏倚。
- 若全部患者入组,检测抗病毒效果所需样本量巨大,随机对照试验可能难以检出显著效果。
- 仅在症状出现后立即入组患者,可大幅降低所需样本量。
核心结论
- 观察性研究中的估计关联可能因个体间病毒动力学异质性大而产生偏倚。
- 随机对照试验中,若全部患者入组,检测显著抗病毒效果所需样本量巨大,可能难以检出。
- 在症状出现后立即招募患者可大幅降低所需样本量。
研究设计与样本
- 建模研究:先分析未抗病毒治疗的SARS-CoV-2纵向病毒载量数据,用宿主内病毒动力学模型拟合。
- 通过聚类方法将拟合的病毒载量分为3组,比较估计参数。
- 通过模拟随机对照试验,加入使病毒复制降低95%至99%的抗病毒效果,假设随机化和治疗在症状出现后有一定时间滞后。
主要发现
- 3组病毒衰减率差异显著(p值<0.001)。
- 3组平均衰减率分别为1.17 d-1(95% CI: 1.06至1.27 d-1)、0.777 d-1(0.716至0.838 d-1)和0.450 d-1(0.378至0.522 d-1)。
- 以病毒脱落持续时间为结局,若全部患者入组,抗病毒效果为95%和99%时,每组所需样本量分别为13,603和11,670(1:1分配)。
- 若仅入组症状出现1天内治疗的患者,抗病毒效果为95%和99%时,每组所需样本量分别降至584和458。
- 使用对数累积病毒载量为结局时,样本量降低结果类似。
临床怎么用
- 设计抗病毒药物随机对照试验时,应考虑仅在症状出现后立即招募患者以大幅降低样本量。
- 分析观察性数据时需注意病毒动力学异质性可能导致的混杂偏倚。
局限性
- 所用常规病毒动力学模型可能无法完全反映SARS-CoV-2病毒动力学的详细机制。
- 模型需在参数设置和模型结构两方面进行校准,才能得到更可靠的样本量计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs have been identified through in vitro and in vivo models, consistent and compelling evidence from clinical studies is limited. The lack of evidence from clinical trials may stem in part from the imperfect design of the trials. We investigated how clinical trials for antivirals need to be designed, especially focusing on the sample size in randomized controlled trials. METHODS AND FINDINGS: A modeling study was conducted to help understand the reasons behind inconsistent clinical trial findings and to design better clinical trials. We first analyzed longitudinal viral load data for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) without antiviral treatment by use of a within-host virus dynamics model. The fitted viral load was categorized into 3 different groups by a clustering approach. Comparison of the estimated parameters showed that the 3 distinct groups were characterized by different virus decay rates (p-value < 0.001). The mean decay rates were 1.17 d-1 (95% CI: 1.06 to 1.27 d-1), 0.777 d-1 (0.716 to 0.838 d-1), and 0.450 d-1 (0.378 to 0.522 d-1) for the 3 groups, respectively. Such heterogeneity in virus dynamics could be a confounding variable if it is associated with treatment allocation in compassionate use programs (i.e., observational studies). Subsequently, we mimicked randomized controlled trials of antivirals by simulation. An antiviral effect causing a 95% to 99% reduction in viral replication was added to the model. To be realistic, we assumed that randomization and treatment are initiated with some time lag after symptom onset. Using the duration of virus shedding as an outcome, the sample size to detect a statistically significant mean difference between the treatment and placebo groups (1:1 allocation) was 13,603 and 11,670 (when the antiviral effect was 95% and 99%, respectively) per group if all patients are enrolled regardless of timing of randomization. The sample size was reduced to 584 and 458 (when the antiviral effect was 95% and 99%, respectively) if only patients who are treated within 1 day of symptom onset are enrolled. We confirmed the sample size was similarly reduced when using cumulative viral load in log scale as an outcome. We used a conventional virus dynamics model, which may not fully reflect the detailed mechanisms of viral dynamics of SARS-CoV-2. The model needs to be calibrated in terms of both parameter settings and model structure, which would yield more reliable sample size calculation. CONCLUSIONS: In this study, we found that estimated association in observational studies can be biased due to large heterogeneity in viral dynamics among infected individuals, and statistically significant effect in randomized controlled trials may be difficult to be detected due to small sample size. The sample size can be dramatically reduced by recruiting patients immediately after developing symptoms. We believe this is the first study investigated the study design of clinical trials for antiviral treatment using the viral dynamics model.
引用
- Iwanami S, Ejima K, Kim KS, et al. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med. 2021. PMID: 34228712. doi:10.1371/journal.pmed.1003660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。